NCT04871932 COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
| NCT ID | NCT04871932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Immune System and Related Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2021-02-01 |
| Primary Completion | 2026-11-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2021-02-01 with a primary completion date of 2026-11-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new understanding of immune cell classification. In particular, the emerging single cell RNA sequencing (scRNA-seq) provides new ideas for the study of cell heterogeneity in multicellular organisms. Analyzing the changes in the expression profile of the cell transcriptome at the single-cell level can clearly show the changes in the trajectory of individual cells, reveal new cell types, and discover the potential functions of immune cells. Therefore, this study intends to recruit healthy adults and use multi-omics techniques such as single-cell sequencing to systematically classify the peripheral blood mononuclear cells of healthy adults to provide a basis for further disease-related research.
Eligibility Criteria
Inclusion Criteria: 1\. Age from 18 to 50 years; 2. No history of major diseases, no history of bacterial or viral infection in the past 3 months; 3. No recent history of surgery or trauma; 4 No history of smoking or alcoholism; 5. No immune system disease. Exclusion Criteria: 1\. Infectious diseases; 2. Tumor diseases; 3. Hematological diseases; 4. History of hypertension and diabetes; 5 Autoimmune diseases; 6 History of liver and kidney insufficiency; 7. History of previous cardiovascular diseases; 8. Pregnancy Or breast-feeding; 9. Past and current use of immunosuppressive drugs
Contact & Investigator
Jun Pu, MD,PhD
PRINCIPAL INVESTIGATOR
Cardiology, Ren Ji Hospital Shanghai, China
Frequently Asked Questions
Who can join the NCT04871932 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Immune System and Related Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04871932 currently recruiting?
Yes, NCT04871932 is actively recruiting participants. Contact the research team at pujun310@hotmail.com for enrollment information.
Where is the NCT04871932 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04871932 clinical trial?
NCT04871932 is sponsored by RenJi Hospital. The principal investigator is Jun Pu, MD,PhD at Cardiology, Ren Ji Hospital Shanghai, China. The trial plans to enroll 50 participants.